Longevity
Every scenario in which longevity is a modeled driver — one risk, read across the whole library.
57 scenarios touch this risk, ranked by probability.
45%▲ 3–10 years
What if Aging ignites a multi-decade eldercare and LTC supercycle?
44%▲ 3–10 years
What if GLP-1s reshape food, beverage and dialysis demand for a decade?
43%▲ 3–10 years
What if Senior-housing REIT boom as the over-80 cohort surges?
41%▲ 3–10 years
What if Multi-cancer early-detection blood tests reach Medicare coverage?
41%▲ 3–10 years
What if Pharma's age-related-disease pipeline rides the aging dividend?
40%▲ 3–10 years
What if Medical-device demand compounds as global over-65s double?
38%▲ 3–10 years
What if CRISPR cures common diseases?
38%▲ 3–10 years
What if Whole-genome screening at birth?
38%▲ 3–10 years
What if Pharma pipeline renaissance: post-cliff growth resumes by 2030?
38%▲ 3–10 years
What if Biomarker-guided launches reshape pharma R&D and launch economics?
38%▲ 3–10 years
What if GLP-1 obesity drugs destroy snack and CPG calorie demand?
38%▲ 3–10 years
What if GLP-1 and anti-aging therapies extend healthspan, lift longevity bets?
37%▲ 1–3 years
What if GLP-1 pills go mass-market?
37%▲ 1–3 years
What if GLP-1 obesity market crosses $100B as Lilly-Novo duopoly compounds?
37%▲ 1–3 years
What if Lilly Zepbound outsells Novo Wegovy as US supply normalizes?
37%▲ 1–3 years
What if GLP-1 cardiovascular and kidney label expansions unlock payer coverage?
37%▲ 1–3 years
What if Oral obesity-pill price war expands access to 50M+ patients?
37%▲ 1–3 years
What if ADC boom rewires oncology and lifts AstraZeneca/Daiichi Sankyo?
37%▲ 3–10 years
What if The 'silver economy' becomes a dominant consumer-spending bloc?
36%▲ 1–3 years
What if IRA 'pill penalty' fix spurs small-molecule R&D rebound?
36%▲ 1–3 years
What if Bispecific and CAR-T pipeline pushes immuno-oncology past chemo era?
36%▲ 1–3 years
What if Alzheimer's anti-amyloid uptake scales after blood-test diagnosis?
36%▲ 3–10 years
What if Longevity/anti-aging clinical proof opens a new pharma growth frontier?
36%▲ 3–10 years
What if Wearables and digital-health diagnostics scale into mainstream care?
36%▲ 3–10 years
What if Japan exports its eldercare-tech and care-robot model globally?
36%▲ 3–10 years
What if Longevity-finance products boom as retirees seek lifetime income?
36%▲ 3–10 years
What if Aging shifts US housing demand from suburbs to walkable senior hubs?
36%▲ 3–10 years
What if Anti-aging biotech breakthrough adds healthy years to the workforce?
35%▲ 3–10 years
What if US Medicare-driven home-health demand powers a services boom?
34%▲ 3–10 years
What if Universal cancer vaccine works?
34%▲ 1–3 years
What if Weight-loss-drug halo lifts the entire metabolic-disease pipeline?
34%▲ 3–10 years
What if GLP-1 reshapes grocery basket toward protein and fresh?
34%▲ 3–10 years
What if Eldercare labor demand creates a structural care-worker wage boom?
34%▲ 3–10 years
What if China's eldercare build-out becomes a domestic-demand growth pillar?
34%▲ 3–10 years
What if Humanoid robots fill eldercare and labor gaps in aging societies?
34%▲ 3–10 years
What if Healthy-aging gains push effective retirement ages higher?
34%▲ 3–10 years
What if Longevity breakthroughs spark a new biotech and healthspan bull?
33%▲ 3–10 years
What if Aging boosts wealth-management and decumulation-services equities?
32%▲ 3–10 years
What if Alzheimer's is reversed?
31%▲ 3–10 years
What if Lab-grown organs end waitlists?
31%▲ 3–10 years
What if Aging-driven demand rebalances the world toward services over goods?
30%▲ 3–10 years
What if AI ends major bottleneck diseases?
29%▲ 1–3 years
What if Gene-therapy reimbursement breakthrough revives one-time-cure model?
29%▲ 1–3 years
What if Specialty-pharma rare-disease launches drive durable high-margin growth?
29%▲ 1–3 years
What if CRISPR in-vivo editing milestone re-rates the gene-editing cohort?
29%▲ 1–3 years
What if Radioligand-therapy boom lifts Novartis and isotope suppliers?
29%▲ 1–3 years
What if Immunology pipeline (oral IL-23/TL1A) sustains big-pharma growth engines?
29%▲ 1–3 years
What if Cardiometabolic outcomes data turns GLP-1s into standard preventive care?
29%▲ 1–3 years
What if mRNA-platform pipeline (oncology, RSV, combos) revives vaccine growth?
29%▲ 1–3 years
What if Biotech breadth thrust as clinical-data wins reopen risk appetite?
29%▲ 1–3 years
What if GLP-1 volume hit drags snack and soda staples lower?
28%▲ 3–10 years
What if A longevity divide fractures society?
27%▲ 3–10 years
What if Healthcare-cost super-inflation from aging entrenches sticky CPI?
24%▲ 3–10 years
What if Longevity drug adds a decade?
22%▲ 1–3 years
What if Beverage-volume decline pressures soda and juice CPG earnings?
21%▲ 6–18 months
What if Lilly orforglipron oral GLP-1 phase-3 win opens mass obesity market?
21%▲ 6–18 months
What if Pfizer/Viking oral GLP-1 readout cracks the Lilly-Novo duopoly?